FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
about
The influence of innate and adaptive immune responses on atherosclerosisFcγ receptors and ligands and cardiovascular diseaseFcγ Receptors in Solid Organ TransplantationGenome-wide association study identifies multiple loci influencing human serum metabolite levelsOxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9Anti-inflammatory immune skewing is atheroprotective: Apoe−/−FcγRIIb−/− mice develop fibrous carotid plaques.Ligation of macrophage Fcγ receptors recapitulates the gene expression pattern of vulnerable human carotid plaquesThe inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) miceGene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice.Reduced Atherosclerosis in apoE-inhibitory FcγRIIb-Deficient Mice Is Associated With Increased Anti-Inflammatory Responses by T Cells and MacrophagesAttenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for interventionVaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis.Adaptive immunity in atherogenesis: new insights and therapeutic approaches.B cells interactions in lipid immune responses: implications in atherosclerotic disease.oxLDL antibody inhibits MCP-1 release in monocytes/macrophages by regulating Ca2+ /K+ channel flowThe role of complement in the development and manifestation of murine atherogenic inflammation: novel avenues.Integration of B cell responses through Toll-like receptors and antigen receptors.The role of Fcγ receptors in atherosclerosis.Molecular biology of atherosclerosis.Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation.
P2860
Q27000370-EA74DB6C-4E8C-4EC8-8A48-D129D3945174Q27021449-BF7AAD5F-798F-484D-8C11-656C83E06725Q28076012-8D00C397-E9EE-456D-8179-88348D09D590Q28258384-2BCE74B5-D46F-465C-9D90-CB5196436A87Q30274903-69FF2ACB-5067-4647-B836-795ECDC9FD00Q30417917-D4FAE01E-85CE-43F8-9BC5-2B06BFC6BC52Q33981389-E0BD2556-397B-4615-B033-86684B8BD9EFQ34644753-E589C72F-F187-42B2-8643-AEBBDFBF23F0Q34785574-44A06DDD-5E05-44BE-BD1A-1567CF0E97C8Q35537314-C0EBB632-78C8-4D6A-A01F-BDAD7EBDBEAFQ35566640-2565AB31-B16E-487E-AD88-83B61527C80FQ35998510-D413B019-4929-4B2D-9F37-65B8EAFAE156Q36279562-19086546-3AAE-4387-A806-12BF122CA6ECQ36497196-DAEA8FA8-8482-4E43-ABBF-40D56351B5CBQ37628580-8E035A79-63E7-4559-A082-F1D9AF5F2EA8Q37747331-FBD8AF12-5036-4712-ACD2-005FED979AFFQ37960811-048216AB-1982-4DEE-9001-EEC4FCB48DA2Q37994060-06A8B5EF-CAEA-4858-87E5-F12C028F97CAQ38017950-BECBE94D-A946-4486-82BB-05A132EB2740Q38125279-0324AB21-F5C5-4284-9B71-B83B6B5A5A26Q46774800-90039D34-3ACE-4EFE-A3F6-E16F11775950
P2860
FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@en
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@nl
type
label
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@en
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@nl
prefLabel
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@en
FcgammaRIIB inhibits the devel ...... otein receptor-deficient mice.
@nl
P2093
P356
P1476
FcgammaRIIB inhibits the devel ...... rotein receptor-deficient mice
@en
P2093
Daniel Kolbus
Gunilla Nordin Fredrikson
Jan Nilsson
Katarina E Olofsson
Maria Wigren
P304
P356
10.4049/JIMMUNOL.0902654
P407
P577
2010-01-22T00:00:00Z